Welcome to our dedicated page for KAZIA THERAPEUTICS SEC filings (Ticker: KZIA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on KAZIA THERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into KAZIA THERAPEUTICS's regulatory disclosures and financial reporting.
Kazia Therapeutics VP, Finance and Controller Jeffrey Bonacorda has reported initial holdings of stock options over American Depositary Shares. The filing shows options over 5,000 ADSs at an exercise price of 0.23 expiring on 2028-06-24, and options over 100,000 ADSs at 6.58 expiring on 2027-07-03. These awards vest in annual installments starting on June 24, 2024 and July 3, 2025, contingent on continued service.
Kazia Therapeutics Ltd director Robert F. Apple filed his initial ownership report, showing two American Depositary Share (ADS) option awards. One ADS option covers 2,000 underlying ADSs at an exercise price of $0.3348 per ADS, expiring on April 30, 2027, and vests in equal quarterly installments over three years beginning on April 30, 2024. A second ADS option covers 75,000 underlying ADSs at an exercise price of $6.58 per ADS, expiring on July 3, 2027, and vests in three equal annual installments beginning on July 3, 2025. Each option converts into ADSs upon exercise, and each ADS may be represented by 500 ordinary shares of Kazia Therapeutics.
Kazia Therapeutics Limited filed a Form F-3 shelf registration to offer up to $200,000,000 of securities, consisting of American Depositary Shares (each representing 500 ordinary shares) and warrants, with specific offerings to be detailed in prospectus supplements.
A prospectus supplement dated March 17, 2026 sets out an at-the-market sales agreement with Leerink Partners LLC for up to $100,000,000 of ADSs. The supplement states sales will be made on an at-the-market basis and that Leerink Partners will receive a 3.0% commission on gross proceeds.
The ADSs trade on Nasdaq under the symbol KZIA; the supplement cites a last reported sale price of $8.01 per ADS on March 12, 2026. Offerings under the shelf and the sales agreement are subject to prospectus supplements and the registration statement becoming effective.
Kazia Therapeutics Ltd ownership filing: Jorey Chernett reports beneficial ownership of 1,412,662 ADS, representing 12.46% of the American Depositary Shares as of February 19, 2026. The percent is calculated using 11,335,991 ADS outstanding as of December 11, 2025, per the issuer's prospectus.
The filing is an amendment to a previously reported Schedule 13G and lists the Reporting Person's principal business address in Bloomfield Hills, Michigan, and U.S. citizenship.
Ikarian Capital, LLC and Neil Shahrestani have filed a Schedule 13G reporting a 5.1% beneficial stake in Kazia Therapeutics Limited. They report beneficial ownership of 580,754 American Depositary Shares, each ADS representing five-hundred ordinary shares of Kazia.
The ADSs may be acquired within 60 days by Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts advised by Ikarian Capital. The holders state the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Kazia.
Kazia Therapeutics Ltd received an amended Schedule 13G filing from Dauntless Investment Group, LLC covering its holdings of Kazia American Depositary Shares. As of the event date of 12/31/2025, Dauntless reports beneficial ownership of 1 American Depositary Share, representing 0.0% of the class.
Dauntless reports no sole or shared voting power over any shares and sole dispositive power over 1 share. The filer identifies itself as a single family office/passive investor and certifies that the securities are not held for the purpose of changing or influencing control of Kazia.
Kazia Therapeutics Limited files a prospectus supplement covering 266,666 American Depositary Shares, representing 133,333,000 ordinary shares, and updates investors using a newly furnished Form 6-K.
The attached report highlights encouraging early results from an ongoing Phase 1b study of paxalisib in late-stage metastatic triple-negative breast cancer. Three patients treated with paxalisib-based regimens have shown meaningful clinical responses, including two partial responses in trial participants and one confirmed complete metabolic response in an expanded access patient.
Paxalisib in combination with pembrolizumab and chemotherapy has been generally well tolerated, with most adverse events deemed unlikely or unrelated to paxalisib and reported paxalisib-related events mainly mild to moderate. Kazia plans to activate additional clinical sites in 2026, aims to enroll twelve triple-negative breast cancer patients by the end of 2026, and anticipates topline data in early 2027.
Kazia Therapeutics Limited files a prospectus supplement covering 95,110 American Depositary Shares (ADSs), which represent 47,555,000 ordinary shares, to update its existing Form F‑1 prospectus with new clinical information from a recent Form 6‑K. The update centers on a Phase 1b study of paxalisib in late‑stage metastatic triple‑negative breast cancer (TNBC) in combination with pembrolizumab and chemotherapy.
In this program, three patients with metastatic TNBC treated with paxalisib‑based regimens have shown meaningful responses: two partial responses in trial participants and one confirmed complete metabolic response in a patient treated under an expanded access program. Paxalisib has been generally well tolerated, with most adverse events considered unlikely or unrelated to the drug and only expected, mainly mild to moderate, paxalisib‑related side effects reported at the 30 mg daily dose.
Kazia plans to activate two additional clinical sites by April 2026 and two more in mid‑2026, targeting enrollment of twelve TNBC patients by the end of 2026 and a topline data readout in early 2027, while continuing broader development of paxalisib and other oncology assets.
Kazia Therapeutics Limited supplements its prospectus covering 232,956 American Depositary Shares, each representing 500 ordinary shares, with a new clinical update on paxalisib in metastatic triple-negative breast cancer (TNBC). The attached Form 6-K details preliminary results from an ongoing Phase 1b study of paxalisib in combination with pembrolizumab and chemotherapy or with olaparib in advanced breast cancer. Three metastatic TNBC patients have shown meaningful responses: two partial responses in trial participants and one confirmed complete metabolic response in an expanded access patient, all remaining on treatment. Paxalisib has been generally well tolerated at a 30 mg daily dose, with mostly mild to moderate expected side effects and two serious adverse events reported as unrelated to paxalisib. Kazia plans to activate additional clinical sites in 2026, target enrollment of twelve TNBC patients by the end of 2026, and expects topline data in early 2027.
Kazia Therapeutics Limited has a prospectus supplement covering 10,700,211 American Depositary Shares, representing 5,350,105,500 ordinary shares, and uses it to incorporate a new clinical update into its existing Form F-1 prospectus. The supplement attaches a Form 6-K that reports preliminary results from an ongoing Phase 1b study of paxalisib in combination with pembrolizumab and chemotherapy in late-stage metastatic triple-negative breast cancer.
The company notes three meaningful clinical responses so far: two partial responses in trial participants and one confirmed complete metabolic response in a patient treated under an expanded access program. Paxalisib has been generally well tolerated with mostly mild to moderate expected side effects, and Kazia plans to activate additional clinical sites in 2026, complete enrollment of twelve TNBC patients by the end of 2026, and target a topline data readout in early 2027.